Ofatumumab outperforms Aubagio in a head to head clinical trial. This isn't a surprise since the average efficacy of Aubagio is in line with the CRAB drugs and Arzerra in line with Rituximab or Ocrelizumab.
Expect Ofatumumab to be approved this fall.
https://multiplesclerosisnewstoday.c...ple-sclerosis/